
aug pm et
summari compani lead wholesal distributor pharmaceut medical-surg
suppli relat product broad rang health care custom
price-to-earnings oper ep
risk assess reflect benefit
diversifi product servic think
strong long-term growth prospect drug health
care suppli distributor develop popul age
expand middl class around world gain
access health care view barrier entri
industri high balanc limit price
power especi current stretch intens
drug price pressur vertic integr
oper litig risk solely-focus drug
distributor view
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
difficult jun-q oper prior
report sever oper challeng
medic segment profit
main concern expect
pharma continu neg stabl profit
declin trend averag
growth yoy pharma howev
sharp drop margin fuel declin
profit vs growth compar
segment
contract renew primari culprit
end mar-q
averag bp better
lead favor surpris
bp prior five quarter
show jun-q drug margin
posit clear leader result
previous held view loom contract
renew could negoti without sharp
declin earn chang
fy jun ep estim
previou strong buy view
mainli valuat driven saw
despit expect declin
rang primari pharma segment
continu headwind medic
segment outlook pharma view
competit strength materi worsen
light jun-q yoy declin oper
profit howev worst drop
segment quarter time
see indic pharma margin
stabil either chanc
roi look gone led goodwil
impair medic segment
quarter recommend hold
risk view includ unresolv cordi
litig drug price pressur potenti
renew effort larg e-commerc
player compet directli drug
distributor contract renew less
favor term loss major custom
target ev/ebitda
materi discount five-year averag
competitor due on-going headwind
medic well materi slower earn
growth pharma competitor
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug specialti drug oncolog
infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut center
focus medic oper canada europ asia
oper margin gener higher medic fy saw medic oper margin versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx recent extend june
market profil accord data iqvia hda research foundat pharmaceut sale
reach cy cy pharmaceut sale move
distribut compani cy remaind move directli manufactur
downstream custom within industri sale specialti drug grow faster
tradit drug specialti grew cy tradit contract result
sale mix shift traditional/specialti cy cy
increas access health insur especi global middl class expand age
popul posit driver health care distribut drug price inflat deflat one
critic factor profit return wareh logist inventori data servic
larg distribut contract typic pay distributor negoti percentag purchas order
amount price often negoti manufactur downstream custom rise drug
price therefor lead larger whole dollar servic fee inflat also help distributor tradit
resal arrang purchas bulk inventori manufactur resel
downstream custom see profit rise lower-cost exist inventori sold new higher
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market share
cy addit gener drug sourc joint ventur larg retail
pharmaci becom standard began collabor jv improv
bargain power gener manufactur set similar jv walgreen
respect
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut pharmaceut sale growth slow
respect slower growth tradit drug busi led
distributor seek higher growth margin segment specialti pharmaceut
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop healthcar provid
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori may patient recoveri acquisit perform accord
plan cordi signific drag earn growth due oper problem inventori
write-down mount litig cost help fuel goodwil impair medic
segment fy
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
financi trend fy achiev compound-annual-growth-rate revenu normal ep
aid share repurchas period ebitda margin fy
redistribut reproduct prohibit without prior written permiss copyright cfra
averag fy gener drug price deflat primari factor
view balanc sheet strong cash ebitda/interest net debt/ebitda
june
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu
neutral sinc august technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
pressur fee distributor receiv
supplier
contributor margin expans
cost control divestitur
under-perform unit profit
stock benefit acquisit
april health
distributor decreas vs
declin composit
sub-industri index fell
versu gain
fundament outlook health care
distributor sub-industri next
month neutral outlook base mainli
favor demand trend see drug
suppli segment gener compris
busi three larg
drug distributor make bulk
market-cap weight sub-industri index
partial off-set drug reimburs drug
price cost pressur expect
distributor benefit new gener
result patent expir mani
large-sel brand drug view
gener import drug distributor
carri wider margin brand
product howev note drug price inflat
like continu moder
restrict gross profit dollar growth
acquisit strateg partner
sector also increas
cardin
drug-sourc contract
caremark partnership support
improv purchas cost greater drug
purchas scale support improv gener
longer term expect larg
distributor realiz high-single-digit
annual ep gain benefit gener drug
penetr age popul drug price
inflat addit see near term
benefit increas american
cover health insur
afford act make
pharmaceut afford note
recent repeal individu mandat
result fewer live cover
next year also see distributor top
line pressur next year
patent loss sever blockbust drug
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi decreas fy ep estim
sep-q ep vs estim result hurt
loss mail order custom may less favor price despit
strong specialti demand improv purchas /joseph agnes
lower target price price-to-earnings
cah averag fy jun ep estim
believ discount warrant given unfavor
drug price trend set fy ep estim jun-q adjust
ep vs estim due lower expect
tax see fy ep hurt cost relat launch new
program pharmaceut segment drive custom growth local
commun educ prevent address opiod crisi tax plan
et cfra keep hold opinion share cardin
keep target price price-to-earnings fy
jun ep estim averag see
valuat hurt unfavor drug price despit medic segment strength
mar-q ep vs estim lower
expect tax pharmaceut distribut hurt gener drug price
pressur partial off-set improv purchas see jun-q comparison
eas lap custom loss fy medic result benefit
improv product mix increas distribut servic /j agnes
et cfra maintain hold opinion share cardin
inc cut target price-to-earnings
averag fy jun ep estim
cut fy ep estim
agre acquir patient recoveri busi
billion cash view deal favor diversifi
busi expand complementari medic product offer
expect fy ep accret reduc fy fy
outlook reflect greater expect deflationari gener drug price
analyst research note compani news
et cfra lower opinion cardin inc share
hold strong buy drop target
use ev/ebitda multipl materi discount five-year averag
competitor due headwind medic segment target reduc
due lower ebitda forecast drop fy jun ep estim
initi jun-q ep vs beat
consensu below-the-lin item yoy ebitda growth
big miss mainli driven primari pharma segment
expect modest margin declin roughli line competitor yet
bp drop jun-q pharma margin far worst drug
distributor caus lose drug margin lead reduc view
abil navig contract renew maintain earn
previous like valuat saw less-domin medic larger
risk view chang due pharma margin pressur particularli
largest custom must renew fy /colin scarola
style text-align justifi target impli
ev/ebitda multipl ebitda discount five-year
averag multipl competitor reflect issu
medic segment keep jun ep estim lower
ep estim view record-high fda drug approv
potenti driver ep growth support guidanc
cah largest custom health corpor
store retail prescript volum growth think recent
sell-off relat may exagger cnbc
report april would shelv health care distribut effort
due difficulti win sticki hospit custom complex
infrastructur regul drug amzn subsequ june
acquisit mail-ord retail pharmaci neutral view
pharmaci custom drug distributor competitor /colin
et cfra keep hold opinion share cardin inc
lower target price-to-earnings near
low end rang fy jun ep estim
see valuat hurt weak medic segment organ trend
unfavor drug price inflat environ cut fy ep estim
mar-q adjust ep vs
estim neg tax impact weaker cordi result revenu
growth line expect pharmaceut segment sale
slightli expect growth exist custom
specialti drug off-set recent loss prime therapeut
contract pharmaceut margin continu pressur low inflat
recent acquisit weaker expect continu challeng
cardiolog endovascular suppli busi cordi see
continu fy /joseph agnes
rais target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi increas fy ep estim
see tax reform increas ep fy
fy dec-q ep vs estim
result benefit strong specialti demand improv purchas /joseph
lower target price-to-earnings
near low end rang fy jun ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
